HealWELL AI Inc.
Research HealWELL AI Inc. (AIDX) on Bullrun: market cap CAD 255.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAIDX
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyCAD
- Market capCAD 255.78M
- Financial periodQ1 2026
- RevenueCAD 33.21M
- Net income-CAD 6.85M
- Free cash flowCAD 3.59M
- Gross margin58.7%
Valuation Snapshot
latest market cap is CAD 255.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 117.18M | -CAD 47.19M | -CAD 23.89M | 52.9% | n/a | CAD 18.63M | CAD 86.13M | CAD 123.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | CAD 255.78M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About HealWELL AI Inc.
Healwell AI Inc. operates as a healthcare technology company in Canada, Australia, and New Zealand. The company operates in two segments, AI and Data Sciences, and Healthcare Software. It focuses on developing and commercializing clinical decision support systems to help healthcare providers detect rare and chronic diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HealWELL AI Inc.'s market cap?
HealWELL AI Inc.'s market capitalization is CAD 255.78M.
What does HealWELL AI Inc. do?
Healwell AI Inc. operates as a healthcare technology company in Canada, Australia, and New Zealand. The company operates in two segments, AI and Data Sciences, and Healthcare Software. It focuses on developing and commercializing clinical decision support systems to help healthcare providers detect rare and chronic diseases. The company provides healthcare artificial intelligence engines, electronic health record platform, healthcare data management and interoperability software, and early/late phase contract clinical research services.